193 related articles for article (PubMed ID: 19450993)
1. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer.
Contreras HR; Ledezma RA; Vergara J; Cifuentes F; Barra C; Cabello P; Gallegos I; Morales B; Huidobro C; Castellón EA
Urol Oncol; 2010; 28(5):534-40. PubMed ID: 19450993
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1, Epithelial-Mesenchymal Transition Markers (E-cadherin/β-catenin) and Neoangiogenesis-related Proteins (PCAM-1 and Endoglin) in Colorectal Cancer.
Mitselou A; Galani V; Skoufi U; Arvanitis DL; Lampri E; Ioachim E
Anticancer Res; 2016 May; 36(5):2271-80. PubMed ID: 27127133
[TBL] [Abstract][Full Text] [Related]
3. Cadherin switching in human prostate cancer progression.
Tomita K; van Bokhoven A; van Leenders GJ; Ruijter ET; Jansen CF; Bussemakers MJ; Schalken JA
Cancer Res; 2000 Jul; 60(13):3650-4. PubMed ID: 10910081
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
Jaggi M; Johansson SL; Baker JJ; Smith LM; Galich A; Balaji KC
Urol Oncol; 2005; 23(6):402-6. PubMed ID: 16301117
[TBL] [Abstract][Full Text] [Related]
5. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
6. Differential immunohistochemical expression of CD44s, E-cadherin and β-catenin among hyperplastic and neoplastic lesions of the prostate gland.
Lazari P; Poulias H; Gakiopoulou H; Thomopoulou GH; Barbatis C; Lazaris AC
Urol Int; 2013; 90(1):109-16. PubMed ID: 23220849
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies.
Mitselou A; Ioachim E; Peschos D; Charalabopoulos K; Michael M; Agnantis NJ; Vougiouklakis T
Exp Oncol; 2007 Mar; 29(1):54-60. PubMed ID: 17431390
[TBL] [Abstract][Full Text] [Related]
8. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA
Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196
[TBL] [Abstract][Full Text] [Related]
9. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells.
Morton RA; Ewing CM; Nagafuchi A; Tsukita S; Isaacs WB
Cancer Res; 1993 Aug; 53(15):3585-90. PubMed ID: 8339265
[TBL] [Abstract][Full Text] [Related]
10. [Expressions of E-cadherin and beta-catenin in LNCaP and ARCaP cell lines and their significance].
Jiang YG; Zhao JH; Luo Y; He DL; Li N; Cui XH; Peng T
Zhonghua Nan Ke Xue; 2009 Oct; 15(10):867-71. PubMed ID: 20112731
[TBL] [Abstract][Full Text] [Related]
11. beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition.
Eger A; Stockinger A; Park J; Langkopf E; Mikula M; Gotzmann J; Mikulits W; Beug H; Foisner R
Oncogene; 2004 Apr; 23(15):2672-2680. PubMed ID: 14755243
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone.
Saha B; Arase A; Imam SS; Tsao-Wei D; Naritoku WY; Groshen S; Jones LW; Imam SA
Prostate; 2008 Jan; 68(1):78-84. PubMed ID: 18008331
[TBL] [Abstract][Full Text] [Related]
13. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival.
Richmond PJ; Karayiannakis AJ; Nagafuchi A; Kaisary AV; Pignatelli M
Cancer Res; 1997 Aug; 57(15):3189-93. PubMed ID: 9242448
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of epithelial and mesenchymal proteins in a panel of prostate cancer cell lines.
Murali AK; Norris JS
J Urol; 2012 Aug; 188(2):632-8. PubMed ID: 22704442
[TBL] [Abstract][Full Text] [Related]
15. KCl cotransporter-3 down-regulates E-cadherin/beta-catenin complex to promote epithelial-mesenchymal transition.
Hsu YM; Chen YF; Chou CY; Tang MJ; Chen JH; Wilkins RJ; Ellory JC; Shen MR
Cancer Res; 2007 Nov; 67(22):11064-73. PubMed ID: 18006853
[TBL] [Abstract][Full Text] [Related]
16. Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer.
Lim SC; Lee MS
Oncol Rep; 2002; 9(5):915-28. PubMed ID: 12168049
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous loss of expression of syndecan-1 and E-cadherin in the embryonic palate during epithelial-mesenchymal transformation.
Sun D; Mcalmon KR; Davies JA; Bernfield M; Hay ED
Int J Dev Biol; 1998 Jul; 42(5):733-6. PubMed ID: 9712528
[TBL] [Abstract][Full Text] [Related]
18. Expression of motility-related protein MRP1/CD9, N-cadherin, E-cadherin, alpha-catenin and beta-catenin in retinoblastoma.
Mohan A; Nalini V; Mallikarjuna K; Jyotirmay B; Krishnakumar S
Exp Eye Res; 2007 Apr; 84(4):781-9. PubMed ID: 17316610
[TBL] [Abstract][Full Text] [Related]
19. Syndecan-1 expression in locally invasive and metastatic prostate cancer.
Chen D; Adenekan B; Chen L; Vaughan ED; Gerald W; Feng Z; Knudsen BS
Urology; 2004 Feb; 63(2):402-7. PubMed ID: 14972511
[TBL] [Abstract][Full Text] [Related]
20. E-cadherin and beta-catenin expression in normal, inflamed and cancerous gallbladder tissue.
Puhalla H; Herberger B; Soleiman A; Filipits M; Laengle F; Gruenberger T; Wrba F
Anticancer Res; 2005; 25(6B):4249-54. PubMed ID: 16309224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
